MD Anderson Cancer Center

Site:	MD Anderson Cancer Center	Go to their website
Address:	1505 Holcombe Blvd.
City:	Houston
State:	TX
Zip:	77030
Country:	USA

59 trials at this site

Phase	Trial	Trial Status	Site Status [asc]	Drug	NCT#
2	Ph II Study of Perifosine Plus Gleevec for Patients With GIST	Completed	Closed	Imatinib + Perifosine	NCT00455559
2	Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery	Terminated	Closed	Imatinib + Oblimersen	NCT00091078
2	Preoperative and Postoperative Imatinib Mesylate Study in Patients With c-Kit Positive GIST (MDACC)	Completed	Closed	Imatinib	NCT00500188
2	Trial of Dasatinib in Advanced Sarcomas	Ongoing, but not recruiting	Closed	Dasatinib (BMS-354825)	NCT00464620
2	Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST) (Novartis CSTI571BUS282)	Completed	Closed	Imatinib	NCT00867113
2	Tasigna Neoadjuvant Gastrointestinal Stromal Tumor (GIST)	Withdrawn	Closed	Nilotinib	NCT01270893
2	A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST	Completed	Closed	Imatinib + AT13387	NCT01294202
2	A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors	Ongoing, but not recruiting	Closed	MEK162 + BYL719	NCT01449058
2	Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib	Completed	Closed	Dovitinib	NCT01831726
2	Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes	Active, not recruiting	Closed	Durvalumab + Tremelimumab	NCT02815995
2	Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study	Active, not recruiting	Closed	CB-839	NCT03872427
1	Phase I Trial of PX-478	Completed	Closed	PX-478	NCT00522652
1	Phase I Trial of Oral PX-866	Ongoing, but not recruiting	Closed	PX-866	NCT00726583
1	Continuous Dosing of Regorafenib in Patients With Advanced Malignancies	Ongoing, but not recruiting	Closed	Regorafenib (BAY 73-4506)	NCT01117623
1	Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients.	Ongoing, but not recruiting	Closed	AUY922	NCT00526045
1	A Multiple Ascending Dose Study of R1507 in Children and Adolescents With Advanced Solid Tumors	Ongoing, but not recruiting	Closed	R1507	NCT00560144
1	Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma	Ongoing, but not recruiting	Closed	PXD101	NCT00413075
1	Monoclonal Antibody IMC-A12 and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer	Ongoing, but not recruiting	Closed	IMC-A12 + CCI-779	NCT00678223
1	IMC-A12 in Combination With Temsirolimus (CCI-779) in Patients With Advanced Cancers	Ongoing, but not recruiting	Closed	IMC-A12 + CCI-779	NCT00678769
1	Phase 1 Study of Intermittent OSI-906 Dosing	Ongoing, but not recruiting	Closed	Linsitinib (OSI-906)	NCT00514306

MD Anderson Cancer Center

59 trials at this site

First | Previous | Page 2 of 3 | Next | Last